Biopeople: Danish Innovation Cluster for Life & Health Sciences

Transcription

1 Biopeople: Danish Innovation Cluster for Life & Health Sciences Fondsmesse Bornholm September 2013 Niels Westergaard, PhD, Dr pharm Science Liaison Officer

2 2

3 Biopeople Biopeople is the Danish Innovation Network & Cluster for the Health & Life Science sectors. Our mission is to help academia and industry to cocreate and develop ideas into new projects, products and services. Biopeople embraces and clusters universities, research organisations, and hospitals, the Danish Medicines Agency, industry associations as well as pharma, medtech, medical device, food and biotech companies. Biopeople is part of the permanent Danish infrastructure for innovation established and cofunded by the Danish Ministry for Science, Innovation and Higher Education, Partners and external projects Cartoons: Jens Hage;

4 Biopeople We focus on setting up: cross disciplinary projects public private partnerships internationalisation. To reach these strategic goals, we use the following services: matchmaking events knowledge transfer, innovation projects strategy development. Cartoons: Jens Hage;

5 Biopeople Biopeople facts Company members: ~135 Company ambassadors: ~150 Partners: 21 Newsletter: 2200 LinkedIn group > 2000 members For more info see;

6 Biopeople 6 Examples of member companies Partners Biogen Idec (Denmark) Manufacturing Chr. Hansen A/S Coloplast A/S Danisco A/S H. Lundbeck A/S Huntingdon Life Sciences LEO Pharma Novo Nordisk A/S Novozymes A/S PerkinElmer Danmark AS Bioneer Central Denmark (Jutland) Region Danish Technological Institute Dansk Biotek DHI Medicoindustrien Region Zealand Roskilde University* Statens Serum Institut The Capital Region of Denmark The Danish Agriculture & Food Council The Danish Association of the Pharmaceutical Industry (Lif) The Danish Medicines Agency The North Denmark Region The Region of Southern Denmark The Technical University of Denmark University of Copenhagen University of Southern Denmark Øresund Food Aalborg University Aarhus University

7 7 Biopeople receives the European Cluster Excellence Initiative (ECEI) Gold Label of Cluster Management Excellence in June Based on expert assessment of 31 quality indicators Endorsed by the European Commission Biopeople is the first European Life Science Network to obtain that recognition

8 8 Biopeople and EU funding Some examples

9 9 48 signed up for the meeting of which 20 came from the private sector and 28 from Universities

10 European Patients Academy on Therapeutic Innovation (EUPATI) The project is receiving support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n , resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/ ) and EFPIA companies.

11 Why patient involvement Industry Are largely unaware about clinical trials, translational research, personalized medicine, pharmacoeconomics - and their potential supportive roles in those areas Paradigm shift Patients Doctors Educate patients to be active in the R&D process - from participation in clinical trials to advising on protocol design, informed consent and ethical review process, marketing authorization, value assessment and healthcare policy

12 Audiences: advocacy leaders and the public at large EUPATI Certificate Training Programme Academic Modular Certificate Programme Patient Ambassadors in committees, R&D teams, Patient Journalists raising awareness Patient Trainers for patient communities & networks 100 patient advocates EUPATI Educational Toolbox Educational resources for patient advocates Variety of distributable formats: Paper-based booklets, presentations, elearning, webinars, videos etc patient advocates EUPATI Internet Library Patients & lay public at large, with low (health) literacy Wiki, YouTube, films and/or cartoons on specific aspects of drug development individuals

13

14 IN2LifeSciences: Market, Technology and Financing access for life &health science SMEs Transnational / multi-biocluster pilot project Stimulates innovation and new business development Creates and improves links between research facilities, markets, financial stakeholders and SMEs across bioclusters Enables innovation and networking in human life sciences SME Benefits Connect with leading international facilities & experts Financial support with almost no administrative burden Use state of art equipment & access regional experts Establish new commercial/scientific relationships

15 IN2LifeSciences Incentives Shared among 8 bioregions, of which Denmark is one ~ 250 incentives: 500, 4000 or 7000 Regional Access Brokers Easy access to facilities and experts

16 Important dates Two page application 1.5 page; who is going to collaborate 0,5 page; on what 3rd round Opening call: September 15, 2013 Closing date: November 30, 2013 Allocation of Incentives: Mid December, 2013 End of the project: July 15, 2014 Probably a 4 th call to come primo 2014

17 17 Horizon 2020 New framework programme for Research and Innovation ( ) Multiannual Financial Framework Euro 90 billion (595 Mia DKK) Increase of 47 % compared to last framework programme Research and innovation increases to 8,5 % of overall EU budget Areas Excellence in the science base (videnskab I topklasse) Tackling societal challenges (samfundsmæssige udfordringer) Industrial leadership and competitive frameworks (industrielt lederskab)

18 Statistik fra FP7 General hjemtag 2.36 % = 5,8 mia DKK Sundhedsordningen 2.9 % = 850 mill DKK (succes rate DK 27,75 % / EU 23,56%) Horizon 2020 Budget på 70 mia Euro 2,36 % = 12,3 mia DKK

19 19

20 De 14 programkomitéer Biopeople

21 Tidslinje - Horizon / Kommissionens forslag 1/ Start på forhandlingerne 31/ Enighed i Rådet om rammeprogrammet ( partial generel approach ) Medio 2012 Primo 2013 Forår 2013 Sidste opslag under FP7 Europa-Parlamentet vedtager sin holdning Rådet og Europa-Parlamentet forhandler september 2013 Rådet og Parlamentet vedtager Horizon / Horizon 2020 starter

22 22 HORIZON 2020 PART 2

23 De 14 programkomitéer Biopeople

24 24 Sundhedsudfordringen Horizon 2020 (Specific programme/særprogram) 1.1 Understand health, well being and disease 1.2 Preventing disease 1.3 Treating and managing disease 1.4 Active ageing and self-management 1.5 methods and data 1.6 health care provision and integrated care

25 Strategien for Sundhedsudfordringen DK-bidrag Fem Temaer: Healthy Ageing Improved prevention and management of Non-communicable (kronisk) diseases Personalised medicine Health systems and integrated care Infectious diseases and resistance

26

27 Focus Areas: Work programme Personalising health and care Sustainable food security Blue growth: unlocking the potential of the oceans Smart cities and communities Competitive low carbon energy Energy Efficiency Mobility for growth Waste Water innovation: boosting its value for Europe Overcoming the crisis Disaster resilience Digital security

28 The Strategic Programme Focus areas Personalising health and care This focus area will support research and innovation throughout the health and care chain by promoting the development of personalised diagnostics, drugs and other interventions by improving health and care delivery through measures including evidence based integrated and self-care by promoting population health interventions. through the Innovative Medicines Initiative bringing together > academia, > small businesses and the > research based pharmaceutical industry through the Ambient Assisted Living Joint Programme bringing together > academia, > small businesses and the > research based pharmaceutical industry through direct support to small businesses or other forms of co operative research

29 29

30 Horizon 2020

31

32 32 The Biopeople Team Per Spindler, Director Jette Claville, Secretary Science Liaison Officers: Niels Westergaard David Featherston Elias Zafirakos Thomas Schou Larsen Sophie Labrosse